During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

New findings argue against a direct causal role for dopamine during the experience of a treatment effect in the establishment of positive treatment expectations and placebo analgesia in healthy ...

For decades, dopamine has been celebrated in neuroscience as the quintessential "reward molecule"—a chemical herald of pleasure, motivation, and reinforcement. In popular understanding, higher ...

They increase dopamine signaling in the brain, producing pleasurable sensations that can encourage repeated use and, over time, lead to addiction. Both endogenous and illicit opioid molecules act on ...